Skip to main content

INDUCCION DE HIPOTERMIA CEREBRAL FOCAL MEDIANTE NANOMATERIALES MAGNETOCALORICOS: UNA NUEVA APROXIMACION TERAPEUTICA PARA EL TRATAMIENTO DEL ICTUS.

SAF2011-30517

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2011
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre FUNDACION PUBLICA GALEGA INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (FIDIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

In Vivo Theranostics at the Peri-Infarct Region in Cerebral Ischemia

  • Agulla Freire, Jesús
  • Brea López, David
  • Campos Pérez, Francisco
  • Sobrino Moreiras, Tomás
  • Argibay González, Bárbara
  • Al-Soufi, Wajih
  • Blanco González, Miguel
  • Castillo Sánchez, José Antonio
  • Ramos Cabrer, Pedro
The use of theranostics in neurosciences has been rare to date because of the limitations imposed on the free delivery of substances to the brain by the blood-brain barrier. Here we report the development of a theranostic system for the treatment of stroke, a leading cause of death and disability in developed countries. We first performed a series of proteomic, immunoblotting and immunohistological studies to characterize the expression of molecular biomarkers for the so-called peri-infarct tissue, a key region of the brain for stroke treatment. We confirmed that the HSP72 protein is a suitable biomarker for the peri-infarct region, as it is selectively expressed by at-risk tissue for up to 7 days following cerebral ischemia. We also describe the development of anti-HSP72 vectorized stealth immunoliposomes containing imaging probes to make them traceable by conventional imaging techniques (fluorescence and MRI) that were used to encapsulate a therapeutic agent (citicoline) for the treatment of cerebral ischemia. We tested the molecular recognition capabilities of these nano-platforms in vitro together with their diagnostic and therapeutic properties in vivo, in an animal model of cerebral ischemia. Using MRI, we found that 80% of vectorized liposomes were located on the periphery of the ischemic lesion, and animals treated with citicoline encapsulated on these liposomes presented lesion volumes up to 30% smaller than animals treated with free (non-encapsulated) drugs. Our results show the potential of nanotechnology for the development of effective tools for the treatment of neurological diseases
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In Vivo Theranostics at the Peri-Infarct Region in Cerebral Ischemia

  • Agulla, Jesús
  • Brea, David
  • Campos, Francisco
  • Sobrino, Tomás
  • Argibay, Bárbara
  • Al-Soufi, Wajih
  • Blanco, Miguel
  • Castillo, José
  • Ramos-Cabrer, Pedro
The use of theranostics in neurosciences has been rare to date because of the limitations imposed on the free delivery of substances to the brain by the blood-brain barrier. Here we report the development of a theranostic system for the treatment of stroke, a leading cause of death and disability in developed countries. We first performed a series of proteomic, immunoblotting and immunohistological studies to characterize the expression of molecular biomarkers for the so-called peri-infarct tissue, a key region of the brain for stroke treatment. We confirmed that the HSP72 protein is a suitable biomarker for the peri-infarct region, as it is selectively expressed by at-risk tissue for up to 7 days following cerebral ischemia. We also describe the development of anti-HSP72 vectorized stealth immunoliposomes containing imaging probes to make them traceable by conventional imaging techniques (fluorescence and MRI) that were used to encapsulate a therapeutic agent (citicoline) for the treatment of cerebral ischemia. We tested the molecular recognition capabilities of these nano-platforms in vitro together with their diagnostic and therapeutic properties in vivo, in an animal model of cerebral ischemia. Using MRI, we found that 80% of vectorized liposomes were located on the periphery of the ischemic lesion, and animals treated with citicoline encapsulated on these liposomes presented lesion volumes up to 30% smaller than animals treated with free (non-encapsulated) drugs. Our results show the potential of nanotechnology for the development of effective tools for the treatment of neurological diseases., Financial support from the Instituto de Salud Carlos III of the Spanish Ministry of Health (projects PI11/02161 and CP09/00074), the Spanish Ministry of Economy and Competence (projects SAF2008-02190, SAF2011-30517 and RETICS-INVICTUS R012/0014), and the European Union (FEDER program) is gratefully acknowledged. Research contracts from the Miguel Servet program (PRC and TS) and the Sara Borrell program (JA and DB) of the Instituto de Salud Carlos III are acknowledged., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In Vivo Theranostics at the Peri-Infarct Region in Cerebral Ischemia

  • Agulla, Jesús
  • Brea, David
  • Campos, Francisco|||0000-0001-8665-1039
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Argibay, Bárbara
  • Al-Soufi, Wajih
  • Blanco, Miguel
  • Castillo, José
  • Ramos-Cabrer, Pedro|||0000-0003-0368-7031
The use of theranostics in neurosciences has been rare to date because of the limitations imposed on the free delivery of substances to the brain by the blood-brain barrier. Here we report the development of a theranostic system for the treatment of stroke, a leading cause of death and disability in developed countries. We first performed a series of proteomic, immunoblotting and immunohistological studies to characterize the expression of molecular biomarkers for the so-called peri-infarct tissue, a key region of the brain for stroke treatment. We confirmed that the HSP72 protein is a suitable biomarker for the peri-infarct region, as it is selectively expressed by at-risk tissue for up to 7 days following cerebral ischemia. We also describe the development of anti-HSP72 vectorized stealth immunoliposomes containing imaging probes to make them traceable by conventional imaging techniques (fluorescence and MRI) that were used to encapsulate a therapeutic agent (citicoline) for the treatment of cerebral ischemia. We tested the molecular recognition capabilities of these nano-platforms in vitro together with their diagnostic and therapeutic properties in vivo, in an animal model of cerebral ischemia. Using MRI, we found that 80% of vectorized liposomes were located on the periphery of the ischemic lesion, and animals treated with citicoline encapsulated on these liposomes presented lesion volumes up to 30% smaller than animals treated with free (non-encapsulated) drugs. Our results show the potential of nanotechnology for the development of effective tools for the treatment of neurological diseases.